To NASDAQ OMX Copenhagen A/S
Announcement no. 05-09 / Copenhagen, 26 February 2009
-Sales of Savene® /Totect® close to being doubled from 2007 to 2008-
Copenhagen, Denmark - 26 February 2009 - TopoTarget A/S (OMX: TOPO) has
announced that sales of Savene® in Europe and Totect® in the US for the
treatment of anthracyclin extravasation accidents with is now trading
profitably in both continents. We have succeeded in gaining close to a doubling
of sales and at the same time streamlining our activities. The total sales in
2008 amounted to DKK 39.1 mio. against DKK 21.6 mio. in 2007. Savene®/Totect®
has now become a profitable and attractive business and we believe the product
will be an important contributor to TopoTarget's activities in the future.
“I'm very proud on behalf of TopoTarget that the sales of Savene®/Totect® are
now in black numbers and I would like to thank our strong and dedicated sales
specialist team for being a crucial factor for making a difference for
patients who have been exposed to this accident with chemotherapy.” Said
professor Peter Buhl Jensen, CEO of TopoTarget.
(For graphics please see the PDF-file)
TopoTarget A/S
For further information, please contact:
Peter Buhl Jensen Telephone +45 39 17 94 99
CEO Mobile +45 21 60 89 22
Background information
About Savene®/Totect®
Savene®/Totect® is a catalytic inhibitor of Topoisomerase II, an enzyme found
in the cell nucleus. Topoisomerase enzymes are essential for cell growth and
proliferation and the target for a group of anti-cancer chemotherapeutics
called anthracyclines. Savene®/Totect® blocks the activity of the topoisomerase
enzyme and prevents the effect of anthracyclines.
Savene®/Totect® is used as a detoxifying agent, administered intravenously as
an antidote following an extravasation. An extravasation is a serious clinical
accident in which anthracyclines accidentally leak into surrounding tissue. The
high concentration of drug causes severe and cumulative damage to the skin,
subcutaneous tissue, muscle and nerves. Current treatment often involves
surgical removal of the tissue followed by plastic surgery and rehabilitation.
The use of dexrazoxane (the active ingredient in Savene®/Totect®) to treat
anthracycline extravasation is protected by patent in several countries
including EU and the US. The US patent number is 6,727,253 B2.
